Makes and markets vitamins, minerals and supplements under the Jamieson brand, sold in Canada and abroad.
Makes and markets vitamins, minerals and supplements under the Jamieson brand, sold in Canada and abroad.
Owns its manufacturing in Canada, which lets it make branded products, private-label products for retailers and contract orders on the same plants, and sells branded products across grocery, drug and club stores. China is served through cross-border online channels and distributors. It bought Youtheory in 2019.
Moat: narrow (brand, distribution). Jamieson is Canada's best-known VMS brand with strong retail shelf space and export relationships.
Headquarters: Toronto, Canada · Founded: 1922 · Employees: 1,346
Size Jamieson Wellness (JWEL.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $1.32B, the 212th largest of 405 Canada companies the cockpit tracks. Shares closed at C$45.70 on 18 Nov 2026.
Performance Over six months the shares gained 31.5%, against -8.1% for the median peer and +1.1% for the Canada market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +9.8%); the operating margin is 13.3% (peer median 16.4%).
Valuation It trades at 20.6× forward earnings against a peer median of 16.5× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points above its cost of capital (7.7% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$885M | C$822M | C$734M | C$676M | C$547M |
| Revenue growth | — | +12% | +9% | +24% | — |
| Gross profit | C$371M | C$338M | C$276M | C$234M | C$198M |
| EBITDA | C$139M | C$133M | C$112M | C$108M | C$101M |
| Net income | C$69.9M | C$62.4M | C$51.9M | C$47.9M | C$52.8M |
| Free cash flow | C$22.6M | C$69.8M | C$52.4M | C$22.9M | C$36.7M |
| Capital expenditure | C$12.4M | C$13.6M | C$10.2M | C$9.31M | C$14.6M |
| Total debt | C$495M | C$445M | C$427M | C$460M | C$467M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jamieson Wellness JWEL.TO | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% |
| Church & Dwight CHD | $26.4B | +16% | +2% | 18% | 28.1× | 7.7% |
| By-health 300146.SZ | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JWEL.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | -2.3% | 9th highest of 21 |
| 6-month return | +31.5% | -8.1% | 4th highest of 21 |
| Distance from 52-week high | -0.4% | -29.8% | highest of 21 |
| Revenue growth (TTM) | +12.1% | +9.8% | 11th highest of 21 |
| Operating margin | 13.3% | 16.4% | 7th lowest of 21 |
| Forward P/E | 20.6× | 16.5× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 13.5% | 2.1% | 5th most demanding of 18 |
| Growth delivered (Del g) | +15.3% | +10.6% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | -1.8 pp | -11.7 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +0.6 pp | +3.7 pp | 6th lowest of 21 |
| EV / EBITDA | 17.3× | 17.4× | 6th cheapest of 12 |
| Net debt / EBITDA | 3.3× | -0.3× | 2nd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |